Can-fite Biopharma Ltd. · TASE:CANF
Can-fite Biopharma — Investor Presentation (October 2013)
20 slides from Can-fite Biopharma's investor presentation, Oct 31, 2013
Slide 1: Can-Fite Investor Presentation – Fall 2013
Can - Fite Investor Presentation – Fall 2013 Pnina Fishman, PhD CEO
Slide 2: Forward Looking Statement
Page 2 This presentation contains forward - looking statements, about Can - Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects . In addition, from time to time, Can -
Slide 3: Company Profile
Page 3 » Can - Fite BioPharma - advanced clinical stage drug development company » Platform technology – A3 Adenosine Receptor Ligands small molecules; addressing multi - billion $ markets: • Autoimmune Inflammatory diseases • Cancer • Ophthalmic diseases » Clinical Development Stage - Phase II and
Slide 4: Equity Profile
Page 4 Equity Profile TASE:CFBI / OTC:CANFY Ticker on Israeli TASE: CFBI Ticker on OTCQB ADR Level II: CANFY Price of ADR: $6.29 (1 ADR = 2 Ordinary Shares) 52 Week Range: $3.30 - $7.00 Shares Out: 16.11 M Ordinary Shares Market Capitalization: $50.7 M Avg. Trading Volume (30 day): 17,284 ADRs As of
Slide 5: Scientific Concept
Page 5 Scientific Concept TASE:CFBI / OTC:CANFY • Why does cancer not metastasize to muscle? • While most of the world asked “Why is there cancer?” we asked the opposite question. ?
Slide 6: From Concept to Technology
Page 6 Drugs for treating inflammatory diseases and cancer APOPTOSIS A 3 AR Muscle Small Molecules Cancer or inflammatory cell From Concept to Technology
Slide 7: Platform Technology: Small Molecule Drugs
Page 7 Platform Technology: Small Molecule Drugs Targeted therapy, specifically aimed at diseased cells • Therapeutic Target – A 3 adenosine receptor (A 3 AR), highly expressed in pathological cells • Drug product – small molecule orally bioavailable drugs, A 3 AR agonists • Pharmacology profile – a
Slide 8: Drug Development Pipeline
Page 8 Drug Development Pipeline TASE:CFBI / OTC:CANFY Indication/Drug Pre - clinical Phase I Phase II Phase III Inflammation Oncology Ophthalmology Psoriasis – CF101 Rheumatoid Arthritis – CF101 Inflammation – CF602 Liver Cancer – CF 102 Dry Eye Syndrome – CF101 Glaucoma – CF101 Uveitis – CF101 Par
Slide 9: Investment Highlights
Page 9 Investment Highlights TASE:CFBI / OTC:CANFY ▪ Platform Technology Addresses Multiple Billion Dollar Markets ▪ $ 5.5 B by 2022 Dry Eye Syndrome (Phase III ) ( * ) ▪ $ 3.3 B per year Psoriasis (Phase II/III) ( ** ) ▪ $ 18 B by 2020 Rheumatoid Arthritis (Phase II) ( *** ) ▪ $ 1.2 B by 2017 Liver
Slide 10: Corporate Partnerships
Page 10 Corporate Partnerships ▪ Tokyo Stock Exchange (Ticker:4548) ▪ Exclusive license to develop and commercialize CF101 in Japan ▪ Up to $20 M in upfront and milestone payments plus up to 12% royalties . Such payments are subject to development and marketing milestones. To date $7.5M has been rec
Slide 11: Ophthalmology Spin-off
Page 11 Ophthalmology Spin - off ▪ Can Fite spun - off all ophthalmic indications of CF101 to OphthaliX ▪ Traded on the OTCQB (Ticker: OPLI ) ▪ Current market cap ~$47M (as of October 28, 2013) ▪ Can - Fite holds 82% of OphthaliX
Slide 12: CF101 – Profile
Page 12 CF101 – Profile • Highly Selective A 3 AR Agonist • Nucleoside derivative • Molecular weight - 510.29 • Water insoluble • Orally bioavailable • Half life time – 8 - 9 hours Chemical Profile Proof of concept in pre - clinical pharmacology studies: • Rheumatoid Arthritis • Osteoarthritis • Inf
Slide 13: Proof of Concept from Phase II Studies
Page 13 Proof of Concept from Phase II Studies Indication Protocol Results Dry Eye Syndrome A Phase II, Randomized, Double - Masked, Placebo - Controlled, Parallel - Group Study of the Safety and Efficacy of Twice Daily CF101 (1 mg) Administered Orally to Patients with Dry Eye Syndrome Dry Eye Syndr
Slide 14: Proof of Concept from Phase II Studies
Page 14 Proof of Concept from Phase II Studies Indication Protocol Results Psoriasis A Phase II/III Randomized, Double - Blind, Placebo - Controlled, Dose - Finding Study of the Efficacy and Safety of Twice Daily CF101 Administered Orally in 288 Patients with Moderate - to - Severe Plaque Psoriasis
Slide 15: CF102 – Profile
Page 15 CF102 – Profile • Highly Selective A3AR Agonist • Nucleoside derivative • Molecular weight - 544.73 • Water insoluble • Orally bioavailable • Half life time – 12 hours Chemical Profile Proof of concept in pre - clinical pharmacology studies: • Hepatocellular Carcinoma • Colon Carcinoma • Pro
Slide 16: CF102 – Primary Liver Cancer – Phase II
Page 16 CF102 – Primary Liver Cancer – Phase II Proof of Concept from Phase II Study Study Protocol: – Phase I/II, open - label, dose - escalation study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered CF 102 in patients with advanced primary liver c
Slide 17: Intellectual Property Portfolio
Page 17 Intellectual Property Portfolio ▪ Exclusive licensee of the U.S. National Institutes of Health (NIH) and Leiden University in the Netherlands for patents covering A3AR Agonists ▪ 15 patent families ▪ 150 patents issued and pending patents applications internationally ▪ IP covers composition
Slide 18: Management Team
Page 18 Management Team TASE:CFBI / OTC:CANFY ▪ Dr. Pnina Fishman, CEO and Scientific Founder ▪ Accomplished scientist; authored or co - authored over 150 publications ▪ Her scientific work is the foundation of Can - Fite’s technology ▪ This work is one of the leading approaches for next - generatio
Slide 19: Financials – Balance Sheet / Income Statement
Page 19 Financials – Balance Sheet / Income Statement TASE:CFBI BALANCE SHEET (ILS=$USD 0.2764 as of June 30, 2013) ASSETS in thousands $USD June 30 th , 2013 LIABILITIES & EQUITY in thousands $USD June 30 th 2013 Current Assets Current Liabilities Cash & Equivalents (1) $4,128 Trade Payables $406 A
Slide 20: Spotlight on Near Future Clinical Milestones
Page 20 Spotlight on Near Future Clinical Milestones Indication Milestone Status Rheumatoid Arthritis Results from Phase II b Trial 80 patient study Data release: Q4 - 2013 Dry Eye Syndrome Results From Phase III Trial 231 patient study Data release: Q4 - 2013 Psoriasis Phase II/III Trial 300 patien
Can-Fite BioPharma — Investor Presentation (October 2013) on 6ix